Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
This single-arm, prospective clinical study will evaluate the efficacy and safety of Zanubrutinib-based maintenance therapy for post-remission in newly diagnosed DLBCL who are intolerant to first-line intensive chemotherapy.
Diffuse Large B Cell Lymphoma
DRUG: Zanubrutinib|DRUG: Lenalidomide
2-year recurrence-free survival, 2 years after enrollment
Overall survival, Overall survival was defined as the time from the date of enrollment to the date of death from any cause., From enrollment to study completion, a maximum of 4.5 years|Overall response rate, ORR at treatment completion or discontinuation defined as the proportion of participants with partial response (PR) or CR at the end of treatment according to the 2014 Lugano Response Criteria; as determined by the investigator and IRC(separately), up to 2 year, at the end of maintenance|Complete response rate, CR rate at the end of treatment by FDG-PET defined as the proportion of participants with CR at the end of treatment according to the 2014 Lugano Response Criteria; as determined by the investigator and IRC (separately), up to 2 year, at the end of maintenance
This single-arm, prospective clinical study will evaluate the efficacy and safety of Zanubrutinib-based maintenance therapy for post-remission in newly diagnosed DLBCL who are intolerant to first-line intensive chemotherapy.